Isabelle Cohen-Codar

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

Jean‐François Delfraissy, Philippe Flandre, Constance Delaugerre et al. · AIDS · 2008 · 137 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Constance Delaugerre, Philippe Flandre, Marie‐Laure Chaix et al. · Antimicrobial Agents and Chemotherapy · 2009 · 54 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients

Anne‐Geneviève Marcelin, Isabelle Cohen-Codar, Martin King et al. · Antimicrobial Agents and Chemotherapy · 2005 · 52 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients

Martin King, Richard A. Rode, Isabelle Cohen-Codar et al. · Antimicrobial Agents and Chemotherapy · 2007 · 41 citations

Life Sciences, Pharmacokinetics, Pharmacotherapy +17

Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial^*

Jade Ghosn, Philippe Flandre, Isabelle Cohen-Codar et al. · HIV Medicine · 2009 · 39 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17